Well Referenced

Tag: GLP-1 receptor agonists

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves

Read More »
June 26, 2025 No Comments

Incretin Hormones and the Satiation Signal

This 2013 review discusses the role of incretin hormones, particularly glucagon-like peptide-1 (GLP-1), in regulating appetite and inducing satiation. GLP-1 is secreted by intestinal L-cells in response to nutrient intake and acts through both peripheral and central pathways to promote feelings of fullness. It slows gastric emptying, enhances insulin secretion,

Read More »
June 26, 2025 No Comments

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

The STEP 8 trial was a 68-week, randomized, double-blind, double-dummy, phase 3 clinical study comparing once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. Participants received lifestyle interventions alongside medication. Semaglutide led to a greater mean weight loss (−15.8%)

Read More »
June 26, 2025 No Comments

Weight Beneficial Treatments for Type 2 Diabetes

This review examines the impact of “weight-friendly” pharmacotherapies in the management of type 2 diabetes mellitus (T2DM), emphasizing the importance of considering the weight effects of different treatment regimens. It highlights that certain antidiabetic agents, such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, are associated with weight neutrality or

Read More »
June 26, 2025 No Comments